TY - JOUR
T1 - Iron Overload via Heme Degradation in the Endoplasmic Reticulum Triggers Ferroptosis in Myocardial Ischemia-Reperfusion Injury
AU - Miyamoto, Hiroko Deguchi
AU - Ikeda, Masataka
AU - Ide, Tomomi
AU - Tadokoro, Tomonori
AU - Furusawa, Shun
AU - Abe, Ko
AU - Ishimaru, Kosei
AU - Enzan, Nobuyuki
AU - Sada, Masashi
AU - Yamamoto, Taishi
AU - Matsushima, Shouji
AU - Koumura, Tomoko
AU - Yamada, Ken ichi
AU - Imai, Hirotaka
AU - Tsutsui, Hiroyuki
N1 - Funding Information:
This work was supported by JSPS KAKENHI ( grants JP16H07049, JP18K15892, and JP21K16090 to Dr Ikeda; JP20K08426 to Dr Ide; and JP18K19405 and JP20H00493 to Dr Yamada ), Uehara Memorial Foundation (to Dr Ikeda), the Japan Foundation for Applied Enzymology (VBIC: Vascular Biology of Innovation; to Dr Ikeda), MSD Life Science Foundation, the Public Interest Incorporated Foundation (to Dr Ikeda); Novartis Pharma Grants for Basic Research 2020 (to Dr Ikeda), Kowa Life Science Foundation (to Dr Ikeda); Center for Clinical and Translational Research of Kyushu University Hospital (to Dr Ide), and AMED-CREST ( grant JP21gm0910013 to Drs Yamada and Imai). Dr Tsutsui has received remunerations from Kowa, Teijin Pharma, Nippon Boehringer Ingelheim, Mitsubishi Tanabe Pharma, Pfizer Japan, Ono Pharmaceutical, Daiichi Sankyo, Novartis Pharma, Bayer Yakuhin, Otsuka Pharmaceutical, and AstraZeneca; manuscript fee from Nippon Rinsho; research funding from Mitsubishi Tanabe Pharma, Nippon Boehringer Ingelheim, IQVIA Services Japan, MEDINET, Medical Innovation Kyushu, Kowa, Daiichi Sankyo, Johnson & Johnson, and NEC Corp; and scholarship funds or donations from Abbott Medical Japan, Otsuka Pharmaceutical, Boston Scientific Japan, Ono Pharmaceutical, Bayer Yakuhin, Nippon Boehringer Ingelheim, St Mary ’ s Hospital, Teijin Pharma, Daiichi Sankyo, and Mitsubishi Tanabe Pharma. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Publisher Copyright:
© 2022 The Authors
PY - 2022/8
Y1 - 2022/8
N2 - Ischemia-reperfusion (I/R) injury is a promising therapeutic target to improve clinical outcomes after acute myocardial infarction. Ferroptosis, triggered by iron overload and excessive lipid peroxides, is reportedly involved in I/R injury. However, its significance and mechanistic basis remain unclear. Here, we show that glutathione peroxidase 4 (GPx4), a key endogenous suppressor of ferroptosis, determines the susceptibility to myocardial I/R injury. Importantly, ferroptosis is a major mode of cell death in I/R injury, distinct from mitochondrial permeability transition (MPT)–driven necrosis. This suggests that the use of therapeutics targeting both modes is an effective strategy to further reduce the infarct size and thereby ameliorate cardiac remodeling after I/R injury. Furthermore, we demonstrate that heme oxygenase 1 up-regulation in response to hypoxia and hypoxia/reoxygenation degrades heme and thereby induces iron overload and ferroptosis in the endoplasmic reticulum (ER) of cardiomyocytes. Collectively, ferroptosis triggered by GPx4 reduction and iron overload in the ER is distinct from MPT-driven necrosis in both in vivo phenotype and in vitro mechanism for I/R injury. The use of therapeutics targeting ferroptosis in conjunction with cyclosporine A can be a promising strategy for I/R injury.
AB - Ischemia-reperfusion (I/R) injury is a promising therapeutic target to improve clinical outcomes after acute myocardial infarction. Ferroptosis, triggered by iron overload and excessive lipid peroxides, is reportedly involved in I/R injury. However, its significance and mechanistic basis remain unclear. Here, we show that glutathione peroxidase 4 (GPx4), a key endogenous suppressor of ferroptosis, determines the susceptibility to myocardial I/R injury. Importantly, ferroptosis is a major mode of cell death in I/R injury, distinct from mitochondrial permeability transition (MPT)–driven necrosis. This suggests that the use of therapeutics targeting both modes is an effective strategy to further reduce the infarct size and thereby ameliorate cardiac remodeling after I/R injury. Furthermore, we demonstrate that heme oxygenase 1 up-regulation in response to hypoxia and hypoxia/reoxygenation degrades heme and thereby induces iron overload and ferroptosis in the endoplasmic reticulum (ER) of cardiomyocytes. Collectively, ferroptosis triggered by GPx4 reduction and iron overload in the ER is distinct from MPT-driven necrosis in both in vivo phenotype and in vitro mechanism for I/R injury. The use of therapeutics targeting ferroptosis in conjunction with cyclosporine A can be a promising strategy for I/R injury.
UR - http://www.scopus.com/inward/record.url?scp=85135946459&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85135946459&partnerID=8YFLogxK
U2 - 10.1016/j.jacbts.2022.03.012
DO - 10.1016/j.jacbts.2022.03.012
M3 - Article
AN - SCOPUS:85135946459
SN - 2452-302X
VL - 7
SP - 800
EP - 819
JO - JACC: Basic to Translational Science
JF - JACC: Basic to Translational Science
IS - 8
ER -